Medication info
Valsartan Tablets 160mg (Valsartan)

Valsartan Tablets 160mg (Valsartan)

Prescription medicationTabletOral
Ingredient · strength
Valsartan›160mg / 1 tablet
Manufacturer / importer
Genewon Science Co., Ltd.
Appearance
Oval film-coated tablet in orange with a gray tint
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 200809910 · Notified 2008.09.29 · Insurance code 671702810

Summary

Main use
Treatment of essential hypertension and heart failure, reduction of the risk of death after myocardial infarction
Who takes it
Adults · Children
Adult dose
(Tablets) * 40, 80, 160 mg 1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take this medication at the same time each day (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg per day or a diuretic may be administered concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg per day. 2) Older adults (aged 75 years or older): Start treatment with 40 mg of this medication once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is needed. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medication once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medication. 4) Patients with reduced intravascular volume: In patients with reduced intravascular volume (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medication once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medication once daily, and do not exceed 80 mg per day. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medication orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medication, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction in the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medication twice daily, followed over several weeks by dose increases to 40 mg, 80 mg, and 160 mg per dose twice daily, taking the patient's tolerability into consideration. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medication may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is needed if creatinine clearance is 10 mL/min or higher. However, do not administer this medication to patients with creatinine clearance below 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medication should preferably not exceed 80 mg. If administering 80 mg or more per day, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Genewon Science Co., Ltd.

Efficacy & effects

Treatment of essential hypertension and heart failure, reduction of the risk of death after myocardial infarction

  • Essential hypertension
  • heart failure
  • left ventricular dysfunction
  • left ventricular systolic dysfunction
View approved original text

This medication is primarily used to effectively lower blood pressure in patients with essential hypertension. It also benefits heart failure patients who are intolerant to ACE inhibitors, specifically those classified as NYHA class II to IV. In clinically stable patients with left ventricular dysfunction after myocardial infarction, this medication contributes to reducing the risk of mortality. Therefore, it is widely used for blood pressure control, heart failure management, and preventive treatment after myocardial infarction.

How to take

Adult dose

(Tablets) * 40, 80, 160 mg 1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take this medication at the same time each day (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg per day or a diuretic may be administered concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg per day. 2) Older adults (aged 75 years or older): Start treatment with 40 mg of this medication once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is needed. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medication once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medication. 4) Patients with reduced intravascular volume: In patients with reduced intravascular volume (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medication once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medication once daily, and do not exceed 80 mg per day. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medication orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medication, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction in the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medication twice daily, followed over several weeks by dose increases to 40 mg, 80 mg, and 160 mg per dose twice daily, taking the patient's tolerability into consideration. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medication may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is needed if creatinine clearance is 10 mL/min or higher. However, do not administer this medication to patients with creatinine clearance below 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medication should preferably not exceed 80 mg. If administering 80 mg or more per day, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during pregnancy, especially in the second and third trimesters, and should be discontinued immediately upon confirmation of pregnancy. Women who are pregnant or may become pregnant, as well as breastfeeding women, should not use this medication. Patients with severely impaired liver function or specific liver diseases should not take this medication. Patients with a history of angioedema or allergies to related medications should avoid this medication. It is also advisable for patients with severe kidney dysfunction not to use this medication. Combining this medication with specific drugs in patients with diabetes or moderate to severe kidney impairment may pose risks. Elderly patients, those with high blood potassium levels, or those with mildly impaired liver function should have their dosage adjusted and conditions closely monitored while using this medication. Patients with heart valve disease or cardiovascular disease should also be cautious of blood pressure changes when taking this medication. Patients with fluid or sodium deficiency may experience hypotension during initial doses, requiring caution. Patients with renal artery stenosis should consider the use of this medication carefully to prevent worsening kidney function. This medication may cause side effects such as dizziness, headache, fatigue, cough, and digestive upset in some patients, so if any abnormal symptoms occur, consult a doctor. If blood pressure drops sharply, discontinue use immediately and seek appropriate measures. Blood pressure, kidney function, and potassium levels should be monitored closely when using other antihypertensives, diuretics, or potassium-sparing agents. Patients post-heart failure or myocardial infarction should have periodic assessments of kidney function while on treatment. Caution is needed for activities like driving or operating machinery due to potential dizziness. Regular blood tests and kidney function tests are advised during the course of this medication. In case of overdose, symptoms may include hypotension and decreased consciousness, and immediate medical attention is required. Keep out of reach of children, and do not transfer the medication to another container for safety.

Side effects

headache

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to prevent air and moisture from entering, and keep it in a cool place away from direct sunlight and heat (below 30 degrees Celsius). This helps maintain the effectiveness of the medication and prevents deterioration.

Appearance and packaging

Appearance

Oval film-coated tablet in orange with a gray tint

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.